US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Follicum reports top-line results from Phase IIa study of FOL-005 for treatment of hair loss (alopecia)

Follicum AB (publ) today reports top-line data from a Phase IIa study of the tissue repairing peptide FOL-005 for treatment of hair loss  (alopecia).  The study examined safety and therapeutic efficacy after daily treatment with the product for four  months. The results confirmed that the treatment was safe and only a few mild side effects were reported. Hair growth increased significantly in the group of patients receiving FOL-005 treatment at the highest dose studied, but no significantly better efficacy compared to the placebo group could be demonstrated. Follicum will  conduct further

Follicum pauses recruitment of patients in Phase II clinical trial of FOL-005 as a result of the ongoing COVID-19 pandemic

Follicum AB ("Follicum" or "the company") today announces that the company has decided to temporarily suspend the phase II study of the drug candidate FOL-005 recently initiated in Germany. This is due to government recommendations in Germany in light of the ongoing outbreak of COVID-19. The company intends to resume the recruitment of patients for the study as soon as the situation in Germany improves.Follicum's Phase II study of FOL-005 was initiated on March 9, 2020 and the recruitment of patients has so far progressed well. The study is being conducted at the Clinical Research Center

First group of patients treated in Follicum's Phase II trial with FOL-005 cream for hair growth stimulation

Follicum AB ("Follicum" or "the company") today announces that the first group of patients have been treated in the new clinical phase IIa study with FOL-005. The study will include approximately 200 male patients with hair loss who are to be treated daily for 4 months with the new formulation of FOL-005 or placebo. The study is being conducted at the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin and at proDerm, Hamburg, Germany.In two previous clinical studies, FOL-005 has been shown to be an effective and safe treatment for hair growth stimulation. The upcoming

There are no items matching the current filter
There are no more items matching the current filter
Back to top